PDCD1 and hepatocellular carcinoma: In conclusion, the interventional therapy (125I seed strand and PVS implantation plus TACE) combined with systemic therapy (lenvatinib plus anti-PD-1 antibody) in patients with HCC and Vp4 PVTT is safe and effective.